Nuchal Translucency and Nasal Bone for Trisomy 21 Screening: Single Center Experience

Monni, Giovanni; Zoppi, Maria A.; Ibba, Rosa M.; Floris, Marcella; Manca, Fabiola; Axiana, Carolina
October 2005
Croatian Medical Journal;2005, Vol. 46 Issue 5, p786
Academic Journal
Aim To evaluate the feasibility and diagnostic accuracy of fetal nuchal translucency and nasal bone assessment at 11-14 weeks for screening of trisomy 21 at a single center. Methods Nuchal translucency measurement and nasal bone evaluation in relation to the fetal karyotype for singleton fetuses were retrospectively assessed at the Ospedale Microcitemico, Cagliari, Italy, in a three-year period (2001-2004). Nuchal translucency was considered enlarged if greater than or equal to the 95th centile for crown-rump length (CRL) of the reference ranges, and nasal bone was described as present or absent during the evaluation of the fetal facial profile. Sensitivity and specificity for trisomy 21 were assessed for nuchal translucency and absent nasal bone. Results Among 32,000 cases recorded in the database including fetuses from 11 to 14 weeks, 16,654 fetuses were included in the study with both nuchal translucency measurement and nasal bone evaluation. Median maternal age was 32 years (range, 14-49). In 854 fetuses (5.1%), nuchal translucency was greater than the 95th centile, and 744 (87.1%) of them had a normal karyotype. Among 141 (0.8%) diagnosed cases of chromosomopathies, there were 96 cases of trisomy 21. Nuchal translucency was enlarged in 110 chromosomopathies and in 72 trisomies 21. Sensitivity was 75.0% (95% confidence interval [CI], 65.5-82.6), and specificity 95.5% (95% CI, 95.2-95.8). In fetuses with enlarged nuchal translucency and normal karyotype, there were 30 structural defects (4%), and among these, 15 heart defects (2%).Measurement of nuchal translucency was possible in all cases where it was attempted. In 13 cases (0.1%), it was not possible to determine the visibility of the nasal bone. In 16,486 cases, the nasal bone was defined as visible and in 155 cases (0.9%) the nasal bone was described as absent. The nasal bone was absent in 56 trisomies 21 and in 23 other chromosomopathies, as well as in 76 normal karyotype fetuses. The sensitivity was 58.3% (95% CI, 48.3-67.7) and specificity 99.5% (95% CI, 99.4-99.6). The sensitivity of enlarged nuchal translucency and nasal bone was 80.2% (95% CI, 71.1-86.9). Conclusions Enlarged nuchal translucency and absent nasal bone are useful markers of trisomy 21 in the first trimester ultrasound screening, increasing the sensitivity of detection of affected fetuses.


Related Articles

  • Conflicting results of prenatal FISH with different probes for Down's Syndrome critical regions associated with mosaicism for a de novo del(21)(q22) characterised by molecular karyotyping: Case report. Eckmann-Scholz, Christel; Gesk, Stefan; Nagel, Inga; Haake, Andrea; Bens, Susanne; Heidemann, Simone; Kautza, Monika; Timke, Christian; Siebert, Reiner; Caliebe, Almuth // Molecular Cytogenetics (17558166);2010, Vol. 3, p16 

    For the rapid detection of common aneuploidies either PCR or Fluorescence in situ hybridisation (FISH) on uncultured amniotic fluid cells are widely used. There are different commercial suppliers providing FISH assays for the detection of trisomies affecting the Down's syndrome critical regions...

  • Sequenom secures IP amid legal charges. Slowik, Elizabeth // Grand Rapids Business Journal;11/23/2009, Vol. 27 Issue 48, p1 

    The article focuses on the licensing rights secured by Sequenom Inc. for the flagship test of the genetic technology based on its SEQureDx tests at its Michigan laboratory. The test reportedly aims to determine the presence of Down syndrome in a fetus through analysis of fetal genetic material...

  • Living It Down. Schmitt, Adam // Teen Ink;Jan2009, Vol. 20 Issue 5, p28 

    The author describes how difficult life is for people inflicted with Down syndrome.

  • Generation of disease-specific induced pluripotent stem cells from patients with different karyotypes of Down syndrome.  // Stem Cell Research & Therapy;2012, Vol. 3 Issue 2, p14 

    The article presents a research study under which fibroblasts from patients with Down syndrome (DS) of various karyotypes were reprogrammed into induced pluripotent stem cells (iPSCs). The study uses the overexpression of four factors: OCT4, SOX2, KLF4, and c-MYC, by using lentiviral vectors. It...

  • Diagnosis of Down's syndrome in neonates. Hindley, D.; Medakkar, S. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Nov2002, Vol. 87 Issue 3, p220 

    The clinical diagnosis of Down's syndrome in the neonatal period has been described as seldom a problem to the neonatologist, but the variable nature of the presenting features is such that the diagnosis can be uncertain. When the diagnosis is suspected, it is good practice to inform the parents...

  • Study: First Trimester is Best Time to Screen Pregnant Women for Fetal Down's Syndrome.  // Ascribe Newswire: Health;11/9/2005, p4 

    The article reports that a new study by researchers for the First- and Second-Trimester Evaluation of Risk Research Consortium has found that the most optimal and accurate time to screen pregnant women for the presence of fetal Down's syndrome is during the first trimester. Researchers reported...


    Focuses on an approach to screening fetuses for Down syndrome that can be performed during the first trimester. Measurement of fetal nuchal translucency; False positive rate of the method.

  • Non-invasive test to predict Down's. Tanday, Sanjay // GP: General Practitioner;2/9/2007, p2 

    The article reports that researchers in the U.S. have found that a non-invasive blood test for expectant mothers could predict whether their unborn child has Down's syndrome. The test compares the number of Single-Nucleotide Polymorphism (SNPs) sites between alleles on chromosomes 21 and 13. The...

  • Seeking other disorders within antenatal serum screening programmes for Down's syndrome. Wald, N.J.; Canick, J.A. // Journal of Medical Screening;Dec2002, Vol. 9 Issue 4, p145 

    Editorial. Illustrates how to search for other disorders, such as trisomy 18, within antenatal serum screening programs for Down's syndrome. Birth prevalence of trisomy 18; Increase in the amniocentesis rate with an associated increase in fetal loss and cost; Effect of adding a separate...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics